LLY

Business Context and Reporting Period

Company: Eli Lilly & Co.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Eli Lilly is a global pharmaceutical company operating primarily in one significant business segment: pharmaceutical products. It also maintains an animal health segment, which is not material to financial statements. The company discovers, develops, manufactures, and sells products in approximately 135 countries. Key therapeutic areas include neuroscience, endocrinology (diabetes), oncology, and cardiovascular diseases.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Worldwide sales increased 6% to $14.65 billion. Growth was driven by new product launches (Cymbalta, Alimta, Forteo) and strong performance in oncology and diabetes care. However, sales were negatively impacted by a $170 million reduction due to wholesaler destocking following a restructuring of U.S. distributor arrangements.
• Product Performance:
  • Zyprexa: Sales declined 5% globally ($4.20 billion) due to decreased U.S. demand and competitive pressures, despite a 9% increase outside the U.S.
  • Cymbalta: Sales surged to $679.7 million following its 2004 launch for depression and diabetic neuropathy.
  • Strattera: Sales declined 17% to $552.1 million due to wholesaler destocking and underlying demand issues.
• Significant Charges:
  • Product Liability: A net pre-tax charge of $1.07 billion was recorded in Q2 2005 related to Zyprexa litigation, including a $700 million settlement fund and reserves for future claims. This reduced EPS by $0.90.
  • Asset Impairments: A pre-tax charge of $171.9 million was recorded in Q4 2005 for asset impairments and restructuring.
• Accounting Changes: The company adopted SFAS 123(R) in 2005, requiring the expensing of stock-based compensation, which increased R&D and marketing expenses. Additionally, the adoption of FIN 47 resulted in a $22.0 million after-tax cumulative effect charge.
• Tax Rate: The effective tax rate dropped to 26.3% in 2005 from 38.5% in 2004. The 2004 rate was elevated by a $465 million tax provision for the repatriation of foreign earnings under the American Jobs Creation Act (AJCA), which was executed in 2005.

Guidance, Outlook, and Risks

• 2006 Guidance:
  • EPS: Expected to be in the range of $3.10 to $3.20.
  • Sales: Expected to grow 7% to 9%.
  • Gross Margin: Expected to improve modestly.
  • Operating Expenses: Expected to grow in the mid-single digits.
  • Tax Rate: Anticipated to be approximately 21%.
• Management Commentary: Management expects continued growth from current products and new launches. The company remains a leader in R&D investment, spending approximately 21% of sales on R&D in 2005. The company repatriated $8.0 billion of foreign earnings in 2005 as planned under the AJCA.
• Key Risks and Contingencies:
  • Zyprexa Litigation: Significant exposure remains regarding product liability claims alleging the drug causes diabetes. While a $700 million settlement was reached for a majority of claims, approximately 150 lawsuits and 825 tolled claims remain. The company is largely self-insured for future losses due to a restrictive insurance market.
  • Patent Challenges: Generic manufacturers have challenged patents for Zyprexa (expiring 2011), Evista, and Gemzar. While the company won a key Zyprexa patent case in April 2005, the decision is under appeal. An unfavorable outcome could materially impact results.
  • Regulatory Investigations: The company is subject to ongoing investigations by the U.S. Attorney's Office regarding marketing practices for Zyprexa, Prozac, and other products, as well as Medicaid rebate reporting. A settlement regarding Evista marketing practices was finalized in 2005 for $36 million.
  • Competition: Intense competition from generic manufacturers and new branded products poses a risk to sales volume and pricing power.

Investor Verification Checklist

• Zyprexa Settlement Finality: Verify the status of the $700 million settlement agreement and the number of remaining active lawsuits and tolled claims.
• Patent Litigation Outcomes: Monitor the appeal of the Zyprexa patent decision and the status of challenges to Evista and Gemzar patents.
• Regulatory Investigation Status: Track developments in the U.S. Attorney's Office investigation into marketing practices and Medicaid rebate reporting.
• Wholesaler Inventory Levels: Assess whether the destocking impact observed in 2005 has stabilized and if future sales growth is organic or driven by inventory rebuilding.
• Insurance Recoveries: Review the company's ability to recover litigation costs from insurance carriers, given the disputes over coverage.
• 2006 EPS Achievement: Compare actual 2006 results against the $3.10–$3.20 EPS guidance, particularly regarding the impact of the Zyprexa patent appeal and new product launches.